Insider Buying: Galectin Therapeutics CEO Purchases 1,000 Shares of Stock (GALT)
Galectin Therapeutics (NASDAQ:GALT) CEO Peter G. Traber purchased 1,000 shares of the stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were purchased at an average price of $4.42 per share, for a total transaction of $4,420.00. Following the acquisition, the chief executive officer now directly owns 97,333 shares of the company’s stock, valued at approximately $430,212. The purchase was disclosed in a filing with the SEC, which is available at this link.
Shares of Galectin Therapeutics (NASDAQ:GALT) traded up 3.04% on Friday, hitting $4.75. 198,456 shares of the company’s stock traded hands. Galectin Therapeutics has a 1-year low of $4.28 and a 1-year high of $19.11. The stock’s 50-day moving average is $10.47 and its 200-day moving average is $12.81. The company’s market cap is $104.7 million.
Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-0.95 earnings per share for the current fiscal year.
A number of research firms have recently commented on GALT. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.